Saint-genis-pouilly, France

Time filter

Source Type

This report assesses future trends in molecular imaging equipment revenues as well as growth in the number of unit shipments over the next few years. This will provide value to market participants that design and manufacture molecular imaging equipment. Market participants will also be provided insights on recent industry and technology trends that are shaping the molecular imaging market. Radiopharmaceutical manufacturers will be provided with key insights on the evolving usage trends of workhorse FDG and Tc-99m radiopharmaceuticals and the increasing adoption of new radiopharmaceuticals across new clinical areas. Companies that are in the process of developing software to improve quantitation accuracy, lower dosages, and reduce scan times for both PET and SPECT will be provided with key insights on how the molecular imaging market is growing as well as the factors that are required to facilitate greater adoption of PET and SPECT technologies. Key Topics Covered: 1. Research Methodology 2. Executive Summary-Molecular Imaging 3. Executive Summary-Radiopharmaceuticals 9. Key Products and Participants 10. Latest Trends Among the Big Three Competitors-Philips Healthcare 11. GE Healthcare 12. Siemens Healthineers 13. Companies to Look Out For 14. Other Issues Impacting Growth Of Molecular Imaging 15. Key Technology and Industry Trends 16. Drivers and Restraints-Total Radiopharmaceuticals Market 17. PET Radiopharmaceuticals Segment 18. SPECT Radiopharmaceuticals Segment 19. Key Products and Participants 20. Key Companies to Look Out For 21. Key Industry Trends 22. Role of New Radiopharmaceuticals in Oncology 23. The Last Word 24. Appendix 25. Medicare Hospital Outpatient Prospective Payment System (HOPPS) Companies Mentioned - Advanced Accelerator Applications - Bio-Nucleonics - Blue Earth - Bracco - Cardinal - Eckert & Ziegler Nuclitec - Eli Lilly - GE - IBA Molecular - Jubilant Draximage - Kimberley-clark - Lantheus - MDS Nordion - Mallinckrodt - Mayo Clinic - Molecular Dynamics - Navidea - NeuSoft - PETNET - Pharmalucence - Philips - Piramal - Siemens Healthineers - Spectrum - Toshiba - UltraSPECT For more information about this report visit http://www.researchandmarkets.com/research/5mxv25/analysis_of_the Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/united-states-molecular-imaging-equipment-and-radiopharmaceuticals-market-2017-2023---research-and-markets-300440832.html


Patent
Advanced Accelerator Applications | Date: 2012-08-10

A process for the preparation of complexes containing ^(68)Ga wherein a buffer formic acid/formate in the presence of compounds capable to sequester metal cations is used in the complexion reaction.


Nucleophile-reactive sulfonated compounds used as precursors to (radio)labelled (bio)molecules are produced by pre-introduction of a nucleophilic compound R* through an unusual nucleophile-induced ring-opening reaction of the sultone moiety of the precursor. The precursors and compounds conform to respective formulae (Ip) and (I): Also disclosed are methods for producing these precursors and compounds, as well as for conjugation of these compounds with (bio)molecules, and to the drugs obtained by this method.


Patent
Advanced Accelerator Applications | Date: 2016-05-24

A process for the preparation of complexes containing ^(68)Ga wherein a buffer formic acid/formate in the presence of compounds capable to sequester metal cations is used in the complexation reaction.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2014-ETN | Award Amount: 2.83M | Year: 2015

Pure accelerated radioisotope beams have been used for 50 years in fundamental physics R&D, e.g. for nuclear structure studies (pear shaped exotic nuclei, Nature 2013); CERN-ISOLDE plays a central role in developing accelerator technologies and fostering collaborative approaches to advance this field of isotope mass separation online. Our most recent contribution was the use of nanomaterial targets for more intense and reliable beam production, and laser ion sources for their purification (discovery of yet unknown 233Francium). Radioisotopes are widely used for functional imaging in medicine, based on 99mTechnetium or on 18Fluorine. This field is expected to rapidly expand, when coupling imaging with new cancer treatments, with isotopes emitting different type of radioactivity, e.g. alpha particles. This is shown with the recently introduced 223Radium chloride (Xofigo) used as a treatment drug in advanced bone cancers. However, either shortage in the supply of 99mTechnetium or lack of access to new radioisotope with adequate properties is a severe treat to develop personalized treatment that combine functional imaging and therapy. Ovarian cancers have poor prognosis, are the second most frequent cancer for women and one of the deadliest. They are difficult to treat, because of possible presence of metastasis, and because this region is difficult to irradiate without collateral damages. MEDICIS-PROMED will train a new generation of scientists to develop systems for personalized Medicine combining functional imaging and treatments based on radioactive ion beam mass-separation. This will be done across a coherent intersectorial multidisciplinary network with world-leading scientists in their field. Subsystems for the development of new radiopharmaceuticals, of isotope mass separators at medical cyclotrons, and of mass separated 11Carbon for PET-aided hadron therapy will be specifically developed to treat the ovarian cancer.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.1.2-1 | Award Amount: 5.85M | Year: 2013

Gastrointestinal stromal tumours (GIST) are a rare disease that metastasises in up to 85% of patients with subsequent median progression-free survival (PFS) of only around 30 months. Tumours are characterised by activating mutations in the KIT or the PDGFRA gene and therefore treatment is mainly based on tyrosine kinase inhibitors designed to block these mutated receptors. However, drug resistance is often based on mutations changing the conformity of the receptor, leaving little effective therapeutic options to these patients. To date, second line chemotherapy offers a median PFS of 6-9 months and external beam radiotherapy is limited by organs at risk close to the tumour. Alternative approaches such as endoradiotherapy or minimally-invasive ablation techniques are effective for local control but are inconsistently used and are not tailored to the individual patients type of disease. To address these issues, we propose a closed-loop personalised treatment concept combining endoscopic-assisted tissue sampling, inline biotechnology and targeted molecular PET imaging probe development combined with minimally-invasive treatment monitored by new functional and metabolic MR imaging techniques. A consistent value chain across European academic centres, research institutes and SMEs will be established for mass spectrometry of tumours, linkage of radiochemical molecular imaging probes, design of new immunocompromised animal models and targeted therapeutic radiopharmaceuticals. This closed-loop platform will minimise fragmentation of treatment approaches by a coherent molecular-based multimodality concept, thus providing new treatment options. On a larger scale, the MITIGATE platform can be expanded to further patient cohorts with oligometastatic diseases such as other sarcomas or renal cell carcinoma. For SMEs the access to new animal models and ligands along with translation into clinical practice will strengthen their market share for new probes and imaging technology.


Grant
Agency: European Commission | Branch: FP7 | Program: MC-ITN | Phase: FP7-PEOPLE-2012-ITN | Award Amount: 3.92M | Year: 2012

The RADIOMI Initial Training Network (ITN) has the goal of providing training in a superbly suited academic and industrial environment uniquely equipped to conduct a scientific research program that addresses one of the key aspects of functional imaging, the underpinning radiochemistry essential for preparation of radiotracers currently difficult or not possible to access. This will be exploited for biomarkers development inclusive of preclinical investigation to maximise research and training output. The network will enhance the European knowledge economy via the provision of trained and mobile researchers equipped with the skills necessary to pursue successful careers across a wide range of employment sectors in the face of increasing global competition. Molecular imaging is a booming research field of critical importance to facilitate diagnosis of disease states, to monitor response to therapy and to streamline the process of pharmaceutical drug development. Upon completion of this ITN, a group of highly skilled radiochemists will be available to carry out cutting edge research in the field of radiotracer development and naturally enhance the global standing of European culture. From a research output point of view, a series of innovative and new concepts for radiolabeling will emerge, thereby facilitating tremendously the production of probes for molecular imaging. Novel biomarkers with preclinical evaluation will be made available upon completion of the project.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: NMP-2009-4.0-3 | Award Amount: 16.52M | Year: 2010

NAMDIATREAM will develop a cutting edge nanotechnology-based toolkit for multi-modal detection of biomarkers of most common cancer types and cancer metastases, permitting identification of cells indicative of early disease onset in a high-specificity and throughput format in clinical, laboratory and point-of-care devices. The project is built on the innovative concepts of super-sensitive and highly specific lab-on-a-bead, lab-on-a-chip and lab-on-a-wire nano-devices utilizing photoluminescent, plasmonic, magnetic and non-linear optical properties of nanomaterials. This offers groundbreaking advantages over present technologies in terms of stability, sensitivity, time of analysis, probe multiplexing, assay miniaturisation and reproducibility. The ETP in Nanomedicine documents point out that nanotechnology has yet to deliver practical solutions for the patients and clinicians in their struggle against common, socially and economically important diseases such as cancer. Over 3.2M new cases and 1.7M cancer-related deaths are registered in Europe every year, largely because diagnostic methods have an insufficient level of sensitivity, limiting their potential for early disease identification. We will deliver Photoluminescent nanoparticle-based reagents and diagnostic chips for high throughput early diagnosis of cancer and treatment efficiency assessment Nanocrystals enabling plasmon-optical and nonlinear optical monitoring of molecular receptors within body fluids or on the surface of cancer cell Multi-Parameter screening of cancer biomarkers in diagnostic material implementing segmented magnetic nanowires Validation of nano-tools for early diagnosis and highly improved specificity in cancer research. OECD-compliant nanomaterials with improved stability, signal strength and biocompatibility Direct lead users of the results will be the diagnostic and medical imaging device companies involved in the consortium, clinical and academic partners


Patent
Advanced Accelerator Applications | Date: 2013-08-30

The present invention is related to new peptide antagonists of _(v)_(3 )receptor, designed on the basis of the crystal structure of integrin _(v)_(3 )in complex with c(RGDf[NMe]V) and the NMR structure of echistatin. These peptides are potent and selective antagonists of the _(v)_(3 )receptor and can be used as novel anticancer drugs and/or new class of diagnostic non-invasive tracers as suitable tools for _(v)_(3)-targeted therapy and imaging.


Patent
Advanced Accelerator Applications | Date: 2015-12-16

A process for the preparation of complexes containing ^(68)Ga wherein a buffer formic acid/formate in the presence of compounds capable to sequester metal cations is used in the complexion reaction.

Loading Advanced Accelerator Applications collaborators
Loading Advanced Accelerator Applications collaborators